These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 18838735)

  • 21. Comments about the severe fracture concept used in the 2012 update of French guidelines for the pharmacological treatment of postmenopausal osteoporosis, by Briot et al.
    Pouilles JM
    Joint Bone Spine; 2012 Oct; 79(5):527-8; author reply 528-9. PubMed ID: 23041470
    [No Abstract]   [Full Text] [Related]  

  • 22. In postmenopausal women with osteoporosis, is zoledronic acid (Reclast) superior in improving T-scores and decreasing fracture rates when compared with placebo?
    Bilbao J; Pugh A; Aspy CB
    J Okla State Med Assoc; 2010 Aug; 103(8):374-5. PubMed ID: 21049709
    [No Abstract]   [Full Text] [Related]  

  • 23. Are we treating women with postmenopausal osteoporosis for their low BMD or high fracture risk?
    Bone HG; Santora AC; Chattopadhyay A; Liberman U
    J Bone Miner Res; 2005 Nov; 20(11):2064-5. PubMed ID: 16234982
    [No Abstract]   [Full Text] [Related]  

  • 24. Bisphosphonates for osteoporosis.
    Favus MJ
    N Engl J Med; 2010 Nov; 363(21):2027-35. PubMed ID: 21083387
    [No Abstract]   [Full Text] [Related]  

  • 25. Use of alendronate after 5 years of treatment.
    Delmas PD
    JAMA; 2007 May; 297(18):1979-80; author reply 1980-1. PubMed ID: 17488957
    [No Abstract]   [Full Text] [Related]  

  • 26. Summaries for patients. Drug therapy for osteoporosis.
    Ann Intern Med; 2008 May; 148(9):I28. PubMed ID: 18458273
    [No Abstract]   [Full Text] [Related]  

  • 27. [Absolute risk for fracture and WHO guideline. Selection of drugs for the prevention of fractures in postmenopausal women].
    Gorai I;
    Clin Calcium; 2007 Jul; 17(7):1090-6. PubMed ID: 17607077
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Persistence with bisphosphonate therapy in older people.
    Melo M; Qiu F; Sykora K; Juurlink D; Laupacis A; Mamdani M
    J Am Geriatr Soc; 2006 Jun; 54(6):1015-6. PubMed ID: 16776810
    [No Abstract]   [Full Text] [Related]  

  • 29. [New bone density conservation agents for osteoporosis under research and development: Minodronic acid].
    Takata S
    Nihon Rinsho; 2007 Nov; 65 Suppl 9():417-20. PubMed ID: 18161142
    [No Abstract]   [Full Text] [Related]  

  • 30. [Osteoporosis].
    Uebelhart B; Rizzoli R
    Rev Med Suisse; 2010 Jan; 6(231):56-60, 62. PubMed ID: 20196435
    [TBL] [Abstract][Full Text] [Related]  

  • 31. EMAS clinical guide: selective estrogen receptor modulators for postmenopausal osteoporosis.
    Palacios S; Brincat M; Erel CT; Gambacciani M; Lambrinoudaki I; Moen MH; Schenck-Gustafsson K; Tremollieres F; Vujovic S; Rees M; Rozenberg S
    Maturitas; 2012 Feb; 71(2):194-8. PubMed ID: 22176952
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The ethics of placebo in studies with fracture end points in osteoporosis.
    Stein CM; Ray WA
    N Engl J Med; 2010 Sep; 363(14):1367-70; discussion e21. PubMed ID: 20879888
    [No Abstract]   [Full Text] [Related]  

  • 33. Use of alendronate after 5 years of treatment.
    Erviti J; Gorricho J
    JAMA; 2007 May; 297(18):1979; author reply 1980-1. PubMed ID: 17488959
    [No Abstract]   [Full Text] [Related]  

  • 34. Use of alendronate after 5 years of treatment.
    Ott SM
    JAMA; 2007 May; 297(18):1979; author reply 1980-1. PubMed ID: 17488958
    [No Abstract]   [Full Text] [Related]  

  • 35. Letter to the Editor: Strontium Ranelate in the Treatment of Osteoporosis: A Possible Mechanism.
    Sugiyama T; Kim YT; Oda H
    J Clin Endocrinol Metab; 2016 May; 101(5):L64-5. PubMed ID: 27163476
    [No Abstract]   [Full Text] [Related]  

  • 36. Lasofoxifene for postmenopausal women with osteoporosis.
    Silva-Fernández L; Andreu JL
    N Engl J Med; 2010 Jun; 362(23):2228; author reply 2228-9. PubMed ID: 20568310
    [No Abstract]   [Full Text] [Related]  

  • 37. [Osteoporotic fracture in menopausal women: alendronate reduces the risk].
    Bize R; Lamy O; Peytremann-Bridevaux I
    Rev Med Suisse; 2008 Dec; 4(183):2703. PubMed ID: 19157286
    [No Abstract]   [Full Text] [Related]  

  • 38. Osteoporosis in postmenopausal women. Therapy options across a wide range of risk for fracture.
    Miller RG
    Geriatrics; 2006 Jan; 61(1):24-30. PubMed ID: 16405361
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Ibandronate once a month].
    Polk B
    Med Monatsschr Pharm; 2006 Jan; 29(1):36-7. PubMed ID: 16463553
    [No Abstract]   [Full Text] [Related]  

  • 40. [Risedronate (Actonel)--from randomized clinical trials to real life].
    Anić B
    Reumatizam; 2007; 54(2):85-6. PubMed ID: 18351152
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.